AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01115114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Liaison
Description: Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
Study NCT02296528 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Swallowing Expansion Device
Description: SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates.
Study NCT01627379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, 5-FU
Description: Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
Study NCT01627379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revisiting the Trauma memories
Description: Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Revisiting the Trauma memories
Description: Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing the trauma memories
Description: The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Processing the trauma memories
Description: The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Memory Retrieval Trial
Description: Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to video clips related to the patient's trauma
Description: Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing retraining
Description: Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Homework
Description: Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
Study NCT03395561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green coffee
Description: 2 capsuls
Study NCT03395561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 2 capsuls
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Homework
Description: Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
Study NCT01574118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compound extinction
Description: The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
Study NCT02558595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacinamide
Study NCT02558595 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill that matches niacinamide pill is size, shape and color
Study NCT02415582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise on treadmill
Study NCT02415582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercises
Description: Combined resistance and aerobic exercise
Study NCT02415582 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: 45 minutes resting sitting
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazides
Description: Capsule (blinded) oral administration once daily for 12 weeks
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril with Thiazide
Description: Capsule (blinded) oral administration 12 weeks
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide plus atenolol
Description: Caspule (blinded) for oral administration once daily for 12 weeks
Study NCT00964301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Education
Description: Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention.
Study NCT00964301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril plus atenolol
Description: Capsule ( blinded) for oral administration once daily for 12 weeks
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril plus atenolol plus thiazide
Description: Capsule (blinded) for oral administration once daily for 12 weeeks
Study NCT03157583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGBUV000A, (Expected SPF 30)
Description: A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
Study NCT03157583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGBUV000B, (Expected SPF 30)
Description: A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
Study NCT03157583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGBUV000C, (Expected SPF 30)
Description: A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
Study NCT03157583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGBUV000D, (Expected SPF 30)
Description: A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
Study NCT03157583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3 Standard, (Expected SPF 16)
Description: A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
Study NCT03157583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen formulation S2
Description: A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
Study NCT03157583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glycerin
Description: A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
Study NCT03891628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Attachment and Biobehavioral Catch-up
Description: Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
Study NCT03891628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Developmental Education for Families
Description: Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
Study NCT03461406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant Grifols
Description: The FE Grifols solution was applied topically via drip or spray application.
Study NCT03461406 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EVICEL
Description: The EVICEL solution was applied topically via drip or spray application.
Study NCT02814123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour inpatient intervention
Description: Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
Study NCT02814123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour inpatient intervention
Description: Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
Study NCT03189758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observational Control Diet
Description: Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
Study NCT04679493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single
Description: The volunteers will receive a single dose of the ID (1 or 2 capsules once)
Study NCT04679493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC7 200 mg multiple
Description: The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
Study NCT04679493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple
Description: The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
Study NCT01275729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
Study NCT03189758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Dietary Sodium Restriction
Description: Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
Study NCT02499250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning (TDFT-12-A2)
Description: The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd.
Study NCT02499250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
Study NCT02499250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
Study NCT04072211 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Engerix-B
Description: Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
Study NCT03844360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: bortezomib was administered follow the doctor's advice.
Study NCT03844360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: eltrombopag was administered follow the doctor's advice.
Study NCT03844360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: imatinib was administered follow the doctor's advice.
Study NCT03844360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib was administered follow the doctor's advice.
Study NCT03844360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: pegaspargase was administered follow the doctor's advice.
Study NCT03844360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Infective Drugs
Description: anti-infective drugs was administered follow the doctor's advice.
Study NCT03844360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
Description: pegaspargase was administered follow the doctor's advice.
Study NCT04165512 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bupivacaine and triamcinolone
Description: a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
Study NCT01578889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG vaccine
Description: Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLYCAP
Description: Capsule for Oral Administration once daily for 12 weeks
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide + Ramipril+Atenolol+Aspirin
Description: Capsule (Blinded) for oral administration once daily for 12 weeks
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Capsule (Blinded) for oral administration once daily for 12 weeks
Study NCT00443794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: capsule (Blinded) for oral administration once daily for 12 weeks
Study NCT04152109 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Without laying on of hands subgroup
Description: The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, around 8 weeks.
Study NCT04152109 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laying on of hands without Spiritual connection
Description: Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, around 8 weeks.
Study NCT01578889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 pDNA adjuvant
Description: Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
Study NCT01578889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV HIV gag vaccine
Description: Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10\^8 plaque-forming units (PFUs) administered as 5x10\^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
Study NCT01578889 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of sodium chloride for injection, USP 0.9%.
Study NCT01578889 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Description: The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
Study NCT01578889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Description: The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
Study NCT00336713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saredutant (SR48968C)
Description: oral administration (capsules)
Study NCT00336713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration (capsules)
Study NCT01288794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics plus human albumin
Description: The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
Study NCT01288794 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diuretics (standard medical treatment)
Description: The patients will receive standard medical treatment (diuretics)
Study NCT02089529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen/Ibumetin with no information, positive information and neutral information
Study NCT01447810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused rigidity bi-valve long arm cast
Description: Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.